CAMP
$5.55
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases.
Intraday
Recent News
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Camp4 Therapeutics (CAMP), 1,070.67% surge in interest Pipeline and key clinical candidates for these companies: Camp4 is developing diseas
CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's Why
CAMP4 Therapeutics Corporation (CAMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Getty Images, Torm, and More Stocks See Action From Activist Investors
Activists also report to the SEC on Vor Biopharma, Camp4 Therapeutics, and Recursion Pharmaceuticals.
Novo files for CagriSema approval; Merck and Pfizer’s trial win
Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer study.
Positive week for Camp4 Therapeutics Corporation (NASDAQ:CAMP) institutional investors who lost 46% over the past year
Key Insights Significantly high institutional ownership implies Camp4 Therapeutics' stock price is sensitive to their...